Traditional cancer therapy, such as radiation, chemotherapy, and surgery, cannot entirely eradicate a patient's malignant disease. Dr. Michael Har-Noy, founder and CEO of the Israeli biotechnology firm Immunovative Therapies Ltd, says, however, that the immune system can be manipulated to eliminate every last cancer cell in a patient's body. Dr. Michael Har-Noy says that an actual cure would result if one could stimulate a patient's immune cascade to seek and kill malignant tissue.
Dr. Michael Har-Noy of Immunovative Therapies, Ltd. has designed a unique immune cascade which he has named the “Mirror EffectTM. The Mirror EffectTM heralds a dramatic improvement in our capacity to use the immune system to eliminate cancer and to neutralize a tumor's ability to evade the immune response. The Mirror EffectTM technology may result in the formation of an entirely new field of cancer therapy. Dr. Michael Har-Noy notes that by patenting and marketing the Mirror EffectTM, Immunovative Therapies, Ltd. could create an immensely profitable.
Dr. Michael Har-Noy and his team at Immunovative Therapies, Ltd. are working with patent attorneys to build a portfolio that protects all the potential applications of the Mirror EffectTM and outlines its use of the immune system to treat some of medicine's the most refractory illnesses. Dr. Michael Har-Noy notes that Immunovative Therapies, Ltd.'s patent portfolio will not only protect the company's unique drugs and methods of manufacturing but may also spawn a new industry based on manipulation of the immune cascade as medical therapy.
Ultimately, says Dr. Michael Har-Noy, Immunovative Therapies, Ltd.'s patent portfolio will likely permanently alter modern oncology Dr. Michael Har-Noy feels that this technology has limitless value.